Walgreens Specialty Pharmacy

Overview

Walgreens Specialty Pharmacy — formerly AllianceRx Walgreens Pharmacy, rebranded August 2024 — is the largest independent specialty pharmacy not directly affiliated with a pharmacy benefit manager. Following Sycamore Partners’ $10 billion take-private of Walgreens Boots Alliance (closed August 28, 2025), the conglomerate was split into five standalone companies: Walgreens (retail + specialty pharmacy), The Boots Group (U.K.), Shields Health Solutions, CareCentrix, and VillageMD.

The entity a pharma commercial operations team contracts with today is materially different from three years ago. Shields Health Solutions — the premier health system specialty pharmacy integrator — was simultaneously established as an independent company and received a $3.5 billion preferred equity investment from Evernorth/Cigna, fundamentally changing its competitive alignment. Walgreens operates under new CEO Mike Motz (former Staples) with a Sycamore-driven cost-reduction focus.

Walgreens Specialty Pharmacy positions itself as the largest independent specialty pharmacy not directly affiliated with a PBM — a commercially significant distinction because it can contract with any payer without formulary and channel conflicts inherent in PBM-owned pharmacies (CVS/Specialty, Express Scripts/Accredo, OptumRx).

Services & Capabilities

Specialty Pharmacy

• 4 central specialty pharmacies (mail-order, high-volume fill)
• ~300 community-based specialty pharmacies (in-store specialty dispensing)
• 1,500+ specialty-trained pharmacists
• 5,000 patient advocacy support staff and Specialty360 care teams
• Services covering nearly 300 million lives
• Enterprise specialty pharmacy revenue: ~$24B (self-reported at launch)

Disease states: Oncology, HIV/AIDS, MS, RA, Crohn’s/IBD, cystic fibrosis, pulmonary fibrosis, bleeding disorders, rare/orphan diseases, neurology, infertility.

Limited Distribution Drug (LDD) Network

265 LDD products as of August 2025, placing it among leading independent LDD networks. Notable 2025 additions include Gilead’s Yeztugo (lenacapavir, twice-yearly HIV prevention), Galderma’s Nemluvio (nemolizumab), and Shorla Oncology’s Imkeldi.

Gene and Cell Therapy

18,000 sq ft Gene & Cell Services Pharmacy in Pittsburgh, PA — first ACHC Gene and Cell Services accreditation (September 2025). Capabilities for supply chain management, logistics, financing, and clinical needs for CAR-T, gene therapies, and one-time-administration products. Also holds ACHC Specialty Pharmacy accreditation with distinctions in oncology, rare diseases, and orphan drugs.

Hub Services (Walgreens Hub Solutions)

Manufacturer-facing hub platform leveraging the 8,500+ Walgreens retail network for prescription rescue and patient enrollment. Includes single point of contact, financial assistance coordination, adherence programs, and dispensing data analytics. Structurally differentiated from pure third-party hubs because prescriptions can be immediately routed to a Walgreens specialty pharmacy.

Clinical Trial Services

20 community-centered clinical trial sites within pharmacy locations (launched June 2022). 17+ million customers engaged; 20% higher enrollment conversion than other recruitment referrals; 63% women, 44% underrepresented groups, 50%+ age 60+. Over 35 pharma partnerships. $100M U.S. government partnership for emergency preparedness trials (August 2024). AstraZeneca AIRE Mobile Unit partnership.

Retail Pharmacy Footprint

~8,500 U.S. retail locations; 78% of U.S. population within five miles. However, 1,200 store closures planned for 2024-2027 (500+ completed by end of 2025) will erode this coverage.

Competitive Position

Dimension	Walgreens Specialty	CVS/Specialty	Express Scripts/Accredo	Health System SPs
PBM alignment	Independent	Captive to CVS Caremark	Captive to Express Scripts	PBM-agnostic
LDD network	265 products	~400+	Embedded in ESI networks	Varies
Community footprint	~300 sites + 8,500 retail	~1,500+ MinuteClinics + CVS retail	Mail/central only	On-site
Gene & cell therapy	Accredited Pittsburgh facility	Yes	Yes	Limited
Clinical trials	20 sites, 17M engaged	Minimal	Minimal	Research hospitals

PBM-affiliated specialty pharmacies control ~80% of U.S. specialty pharmacy claims by routing. Walgreens Specialty’s ~5-10% share reflects its independence — it must win each manufacturer contract and payer access agreement on merit without captive PBM routing.

Recent Developments

• Walgreens Specialty Pharmacy Launch (April 2024): Consolidation of specialty assets into single branded entity with Pittsburgh gene/cell facility.
• Sycamore Partners Take-Private (August 2025): $10B equity value (~$23.7B total including debt). Split into five standalone companies.
• Shields Separation + Evernorth Investment (September 2025): Shields became independent; $3.5B Evernorth preferred equity creates competitive tension with Walgreens Specialty.
• S&P Downgrade to BB- (December 2024): Sub-investment grade; adjusted debt/EBITDA of 5.8x.
• Post-Acquisition Restructuring (2026): 628 corporate positions eliminated February 2026; Houston distribution center closed; store closure pace moderated.
• ACHC Gene and Cell Services Accreditation (September 2025): First-of-its-kind accreditation validating advanced therapy capabilities.

Financial Profile

Last public fiscal year: FY2024 (ended August 31, 2024)

Metric	FY2024
Total revenue	$147.7B
U.S. Retail Pharmacy revenue	$115.8B (78%)
Enterprise specialty pharmacy revenue	~$24B (self-reported)
S&P credit rating (Dec 2024)	BB-
Adjusted debt/EBITDA	5.8x

Post-privatization (August 2025): ~$13.7B in debt retired at close. Post-restructuring debt/EBITDA targeted at ~4.5x by 2026. WBA is no longer a reporting company; financial disclosures are minimal.

Sources

Primary source: raw/research/04_walgreens_boots_alliance.md. Data from WBA 10-K FY2024, S&P Global, Drug Channels Institute, Forbes, AP News, Chain Drug Review.